Subscribe to Updates
Get the latest business software news from BitComme.
Browsing: Therapeutics
Calif., Sept. 25, 2026/PRNewswire/ –KaliTherapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced its selection as a winner of the 2026 Endpoints 11, the annual list of the 11 most promising private biotechnology companies curated by the Endpoints News editorial team
Up to $35 million from the Gates Foundation will support ProFound’s use of its platform, datasets, and algorithms to identify new drug targets and biomarkers for preeclampsia and eclampsia
Axsome Therapeutics (NASDAQ: AXSM), a biotech company, has performed fairly well this year. The company’s shares are up 16% versus the S&P 500’s 11%. Could the stock rise even higher? Wall Street certainly thinks so. Axsome Therapeutics’ average price target (according to Yahoo! Finance) of $285.42 implies about a 37% upside from its current level.…
Silence Therapeutics and AbCellera launched respective common share public offerings, and Beyang Therapeutics and Remepy closed $30+ million oversubscribed Series A rounds.